Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Paul Musto"'
Autor:
Luis Chu, Paul M. Hyman, Jacob D. Soumerai, Steven P. Treon, Johannes C. Nunnink, Joseph J. Kash, Zachary R. Hunter, Christopher J. Patterson, Nikhil C. Munshi, Ari David Baron, Paul Musto, Terenig O. Terjanian, Leukothea Ioakimidis, David J. Sharon, Andrew R. Branagan, Elena L. Nawfel, Kenneth C. Anderson
Publikováno v:
Clinical Cancer Research. 15:355-360
Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c6e43b9baf44ddd2cb2e675eeae4fa
https://doi.org/10.1158/1078-0432.ccr-08-0862
https://doi.org/10.1158/1078-0432.ccr-08-0862
Autor:
Mark W. Pasmantier, Andrew R. Branagan, Henry Sonneborn, Bryan Ciccarelli, Jacob D. Soumerai, Zachary R. Hunter, David R. Lovett, Leukothea Ioakimidis, Kenneth C. Anderson, John M. Howard, Robert B. Cooper, Paul Musto, Hans Boedeker, Steven P. Treon, Alan Rauch, Cynthia Chua, Lawrence Garbo, Luis Chu, Maria Moore, John M. Hill, Frederick M. Briccetti, Stephen H. Nantel, Evdoxia Hatjiharissi, Harvey Zimbler, Christopher J. Patterson
Publikováno v:
Blood. 112:4452-4457
Thalidomide enhances rituximab-mediated, antibody-dependent, cell-mediated cytotoxicity. We therefore conducted a phase 2 study using thalidomide and rituximab in symptomatic Waldenstrom macroglobulinemia (WM) patients naive to either agent. Intended
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9473f8afb3aa3b60dccee974d0688c
https://doi.org/10.1182/blood-2008-04-150854
https://doi.org/10.1182/blood-2008-04-150854